Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid

Completed 12 enrolled Norwegian University of Science and Technology St. Olavs Hospital · collab

NaSingle-groupOpen-labelBasic science

Summary

Overdose with potential deadly outcome is a serious problem among opioid abusers, not least in Norway. To save lives, immediate treatment with a μ-opioid antidote such as naloxone is required. The purpose of this study is to explore the pharmacokinetics and pharmacodynamics of naloxone in healthy volunteers under opioid influence.

Timeline

Start: 2015-04
Primary completion: 2016-02
Completion: 2016-02

Publications

Results Tylleskar I, Skulberg AK, Skarra S, Nilsen T, Dale O. Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil. Eur J Clin Pharmacol. 2018 Dec;74(12):1547-1553. doi: 10.1007/s00228-018-2545-y. Epub 2018 Aug 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naloxone	Small molecule	1 mg	Intravenous
Subject	Remifentanil	Small molecule	1.3 ng/ml	Intravenous

Indications

No indication recorded.